Progyny (NASDAQ:PGNY) CEO Sells $419,417.07 in Stock

Progyny, Inc. (NASDAQ:PGNY) CEO Peter Anevski sold 11,939 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $35.13, for a total value of $419,417.07. Following the transaction, the chief executive officer owned 797,572 shares of the company’s stock, valued at $28,018,704.36. This trade represents a 1.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Peter Anevski also recently made the following trade(s):

• On Monday, November 9th, Peter Anevski sold 161,308 shares of Progyny stock. The shares were sold at an average price of $35.73, for a total value of $5,763,534.84.

Progyny Price Performance

Shares of PGNY traded up $1.11 during trading hours on Monday, hitting $35.95. The stock had a trading volume of 1,645,331 shares, compared to its average volume of 914,017. The stock has a market capitalization of $2.76 billion, a price-to-earnings ratio of 32.98, a P/E/G ratio of 2.08 and a beta of 0.97. The company’s fifty day moving average is $27.65 and its two-hundred day moving average is $24.64. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $36.00.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. Progyny had a return on equity of 19.23% and a net margin of 6.80%. The business had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. During the same period in the prior year, the company earned $0.15 EPS. Progyny’s revenue for the quarter was up 8.9% on a year-over-year basis. Equities analysts predict that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on PGNY shares. Wells Fargo & Company lifted their price target on Progyny from $37.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday. Zacks Research cut shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 19th. JPMorgan Chase & Co. raised their price objective on shares of Progyny from $30.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday. Truist Financial boosted their target price on shares of Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Finally, Canaccord Genuity Group set a $35.00 target price on shares of Progyny in a research report on Friday, August 7th. Eleven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Progyny has an average rating of “Moderate Buy” and an average price target of $35.33.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Intech Investment Management LLC raised its stake in shares of Progyny by 33.3% during the third quarter. Intech Investment Management LLC now owns 59,521 shares of the company’s stock worth $1,499,000 after buying an additional 14,864 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in Progyny by 14.4% in the third quarter. Hantz Financial Services Inc. now owns 4,124 shares of the company’s stock valued at $104,000 after acquiring an additional 520 shares during the last quarter. William Blair Investment Management LLC boosted its stake in Progyny by 10.7% in the third quarter. William Blair Investment Management LLC now owns 645,130 shares of the company’s stock valued at $16,251,000 after acquiring an additional 62,178 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Progyny by 465.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 128,417 shares of the company’s stock worth $3,213,000 after acquiring an additional 105,707 shares during the period. Finally, Maryland State Retirement & Pension System grew its holdings in Progyny by 62.0% during the 3rd quarter. Maryland State Retirement & Pension System now owns 17,044 shares of the company’s stock worth $429,000 after acquiring an additional 6,526 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment.

The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.

Founded in 2008, Progyny serves employer clients and their workforces in the United States.